This year's International Symposium on Liver Diseases (IISLD) 2024, held in the San Diego Convention Center, includes two key ...

In a report released on October 10, David Evans from Kepler Capital maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), ...

Daryl Brown, who was prescribed the antidepressant Seroxat in childhood because of his Tourette’s syndrome and OCD, tells ...

GSK settles 93% of Zantac lawsuits with a $2.2 billion payout, easing investor concerns. However, doubts over its future ...

Cerebras is playing in a huge market with insatiable investor demand, but its IPO prospectus is littered with red flags that ...

As one of the largest pharmaceutical and vaccine companies, GSK has used its vast resources to create the next generation of healthcare treatments. The company's innovative new product lineup and ...

GSK's share price rose 6% after settling 93% of Zantac cases, impacting Q3 earnings; forward non-GAAP P/E remains reasonable ...

Shares slipped in New York and Europe Thursday as the latest US inflation report strengthened the case for a slower pace of ...

Shares of the UK-based pharma giant GlaxoSmithKline PLC ($GB:GSK) soared over 6% after the company announced a settlement of ...

The settlement, which is at the low end of Jefferies analysts’ $2 billion to $3.5 billion estimate, will resolve 93% of the ...

San Antonio attorney Mikal Watts is among a group of lawyers that negotiated a settlement of as much as $2.2 billion to resolve claims by about 80,000 people who allege a discontinued version of the ...

UK-based pharmaceutical giant GSK, or GlaxoSmithKline, has announced that it has agreed to settle nearly 80,000 state-level ...